Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.